跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT05537025
NCT05537025已完成1 期

A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals24 个研究点 分布在 6 个国家目标入组 105 人开始时间: 2023年1月30日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
105
试验地点
24
主要终点
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Over Time
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —（Adult, Older Adult）
性别
All
接受健康志愿者
是

入选标准

  • •Normal pulmonary function tests at Screening
  • •Normal electrocardiogram (ECG) at Screening
  • •Non-smoking
  • •Female participants cannot be pregnant or lactating
  • •Male and female participants of childbearing potential must agree to use highly effective contraception and must not donate eggs/sperm during the study and for at least 90 days following end of study or last dose of study drug, whichever is later.
  • •Inclusion Criteria (IPF Participants):
  • •Age ≥ 45 years at Screening
  • •Clinical diagnosis consistent with IPF based upon established criteria confirmed by review of high-resolution computed tomography (HRCT) and surgical lung biopsy findings (if available)
  • •Safely able to undergo bronchoscopy
  • •Stable IPF disease at Screening with minimum life expectancy of ≥ 12 months from Screening
  • •Female participants cannot be pregnant or lactating
  • •Male and female participants of childbearing potential must agree to use highly effective contraception and must not donate eggs/sperm during the study and for at least 90 days following end of study or last dose of study drug, whichever is later.

排除标准

  • •Acute lower respiratory infection within 30 days prior to first dose or acute upper respiratory infection within 7 days prior to first dose
  • •Positive coronavirus disease (COVID-19) test during Screening window
  • •Any history of chronic pulmonary disease or anaphylaxis
  • •Human immunodeficiency virus (HIV) infection, seropositive for hepatitis B virus (HBV), seropositive for hepatitis C virus (HCV)
  • •Uncontrolled hypertension
  • •History of significant cardiac disease
  • •History of major surgery within 12 weeks prior to first dose
  • •Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
  • •Use of illicit drugs
  • •Use of an investigational agent or device within 30 days prior to first dose
  • •Exclusion Criteria (IPF Participants):
  • •Interstitial lung disease (ILD) associated with known primary cause
  • •Positive COVID-19 test during Screening window
  • •IPF exacerbation within 6 weeks prior to first dose
  • •Lower respiratory tract infection requiring antibiotics or antivirals within 30 days prior to first dose
  • •Smoking cigarettes or e-cigarettes within 3 months prior to first dose
  • •Use of systemic corticosteroid therapy within 30 days prior to first dose
  • •Initiation or cessation of antifibrotic therapy or change of antifibrotic dose regimen within 10 weeks prior to first dose
  • •Any history of lung transplant or plan to undergo transplant during the course of the study
  • •Any concomitant pulmonary disease that could interfere with the evaluation of the study drug or interpretation of patient safety or study results
  • •HIV infection, seropositive for HBV, seropositive for HCV
  • •Uncontrolled hypertension
  • •History of significant cardiac disease
  • •History of major surgery within 12 weeks prior to first dose
  • •Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
  • •Use of illicit drugs
  • •Use of an investigational agent or device within 30 days prior to first dose
  • •Note: additional inclusion/exclusion criteria may apply per protocol

研究组 & 干预措施

ARO-MMP7

Experimental

single or multiple doses of ARO-MMP7 by inhalation of nebulized solution

干预措施: ARO-MMP7 Inhalation Solution (Drug)

Placebo

Placebo Comparator

single or multiple doses of placebo by inhalation of nebulized solution

干预措施: Placebo (Drug)

结局指标

主要结局

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Over Time

时间窗: From first dose of study drug through the end of study (EOS; up to 85 days, or until sputum MMP7 protein concentration is ≥ 70% of the baseline value, whichever is later)

Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

时间窗: Day 1 up to Day 85

An adverse event (AE) was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to study drug. TEAEs were defined as AEs with onset after administration of the study drug, or when a pre-existing medical condition increases in severity or frequency after study drug administration. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

次要结局

  • Change From Baseline Over Time in Forced Vital Capacity (FVC)(Baseline through EOS (up to 85 days, or until serum MMP7 protein concentration is ≥ 70% of the baseline value, whichever is later))
  • PK of ARO-MMP7: Renal Clearance (CLr) in NHVs(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30)
  • Change From Baseline Over Time in Forced Expiratory Volume (FEV1)(Baseline through EOS (up to 85 days, or until serum MMP7 protein concentration is ≥ 70% of the baseline value, whichever is later))
  • Change From Baseline Over Time in Diffusing Capacity for Carbon Monoxide (DLCO)(Baseline through EOS (up to 85 days, or until serum MMP7 protein concentration is ≥ 70% of the baseline value, whichever is later))
  • PK of ARO-MMP7: Maximum Observed Plasma Concentration (Cmax)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Area Under the Plasma Concentration versus Time Curve from Zero to 24 Hours (AUC0-24)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Terminal Elimination Half-Life (t1/2)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Apparent Systemic Clearance (CL/F)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Area Under the Plasma Concentration versus Time Curve from Zero to the Last Quantifiable Plasma Concentration (AUClast)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Area Under the Plasma Concentration versus Time Curve from Zero to Infinity (AUCinf)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Apparent Terminal Phase Volume of Distribution (VZ/F)(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30, and (IPF only) Days 8, 22, and 36)
  • PK of ARO-MMP7: Recovery of Unchanged Drug in Urine Over 0 to 24 Hours (Amount excreted; Ae) in NHVs(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30)
  • PK of ARO-MMP7: Percentage of Administered Drug Recovered in Urine Over 0 to 24 Hours in NHVs(single dose phase: up to 168 hours post-dose; multiple dose phase: up to 6 hours post-dose on Days 1 and 15 or 29, 24 hours post-dose on Days 2 and 30)
  • IPF Cohorts: Tmax of ARO-MMP7(Pre-dose up to 6 hours post-dose on Days 1, 15, and 29)
  • SAD Cohorts: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) of ARO-MMP7(Pre-dose up to 24 hours post-dose (Day 2))
  • MAD Cohorts: AUC0-24 of ARO-MMP7(Pre-dose up to 24 hours post-dose on Days 1, 15, and 29)
  • IPF Cohorts: AUC0-24 of ARO-MMP7(Pre-dose up to 24 hours post-dose on Days 1, 15, and 29)
  • SAD Cohorts: Time to Reach Cmax (Tmax) of ARO-MMP7(Pre-dose (Day 1) up to 168 hours post-dose (Day 8))
  • MAD Cohorts: Tmax of ARO-MMP7(Pre-dose up to 6 hours post-dose on Days 1, 15, and 29)
  • Change From Baseline to the End of Study (EOS) in Forced Expiratory Volume in One Second (FEV1)(Baseline, EOS (up to Day 85))
  • Change From Baseline to the EOS in Forced Vital Capacity (FVC)(Baseline, EOS (up to Day 85))
  • Change From Baseline to the EOS in Diffusing Capacity for Carbon Monoxide (DLCO)(Baseline, EOS (up to Day 85))
  • SAD Cohorts: Maximum Observed Plasma Concentration (Cmax) of ARO-MMP7(Pre-dose (Day 1) up to 168 hours post-dose (Day 8))
  • MAD Cohorts: Cmax of ARO-MMP7(Pre-dose up to 6 hours post-dose on Days 1, 15, and 29)
  • IPF Cohorts: Cmax of ARO-MMP7(Pre-dose up to 6 hours post-dose on Days 1, 15, and 29)
  • Urine PK of ARO-MMP7: Recovery of Unchanged Drug in Urine Over 0 to 24 Hours (Amount Excreted; Ae) in NHVs Enrolled in SAD Cohorts(Pre-dose up to 24 hours post-dose on Day 1)
  • Urine PK of ARO-MMP7: Percentage of Administered Drug Recovered in Urine Over 0 to 24 Hours (Fraction Excreted; fe) in NHVs Enrolled in SAD Cohorts(Pre-dose up to 24 hours post-dose on Day 1)
  • Urine PK of ARO-MMP7: Renal Clearance (CLr) in NHVs Enrolled in SAD Cohorts(Pre-dose up to 24 hours post-dose on Day 1)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (24)

Loading locations...

相似试验

终止
1 期
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung DiseaseAsthmaChronic Obstructive Pulmonary Disease
NCT05292950Arrowhead Pharmaceuticals78
已完成
1 期
Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseaseAsthma
NCT05276570Arrowhead Pharmaceuticals127
已完成
1 期
Study of ARO-RAGE in Healthy SubjectsAsthma
NCT05533294Arrowhead Pharmaceuticals43
已完成
1 期
Study Evaluating AMG 386 in Adult Patients With Advanced Solid TumorsTumors
NCT00102830Amgen
终止
1 期
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic MelanomaMetastatic MelanomaMalignant Metastatic MelanomaMelanomaAdvanced Melanoma
NCT01212276Morphotek18